Ticker Details
TG Therapeutics, Inc. TG Therapeutics Inc is a biopharmaceutical company. It is engaged in the acquisition, development & commercialization of novel treatments for B-cell malignancies and autoimmune diseases.
IPO Date:	June 1, 2010
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$5.53B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.46 | 3.11%
Avg Daily Range (30 D):	$0.59 | 1.98%
Avg Daily Range (90 D):	$0.58 | 1.93%

Institutional Daily Volume
Avg Daily Volume:	1.65M
Avg Daily Volume (30 D):	1.72M
Avg Daily Volume (90 D):	1.55M

Trade Size
Avg Trade Size (Sh.):	115
Avg Trade Size (Sh.) (30 D):	70
Avg Trade Size (Sh.) (90 D):	69

Institutional Trades
Total Institutional Trades:	5,932
Avg Institutional Trade:	$2.89M
Avg Institutional Trade (30 D):	$4.79M
Avg Institutional Trade (90 D):	$3.99M
Avg Institutional Trade Volume:	.15M
Avg Institutional Trades (Per Day):	2

Market Closing Trades
Avg Closing Trade:	$5.17M
Avg Closing Trade (30 D):	$10.71M
Avg Closing Trade (90 D):	$8.9M
Avg Closing Volume:	264.58K

News

Feb 8, 2026 @ 9:17 PM TG Therapeutics Announces Collaboration with Chris... Source: Tg Therapeutics, Inc.

Jan 14, 2026 @ 1:36 PM Stock Market Today: S&P 500, Dow Jones, Nasdaq 100... Source: Rishabh Mishra

Nov 10, 2025 @ 9:00 PM TG Therapeutics to Participate in the TD Cowen Imm... Source: Tg Therapeutics, Inc.

Aug 4, 2025 @ 4:23 PM TG Therapeutics Q2 Revenue Up 91% Source: Jesterai

May 5, 2025 @ 11:00 AM TG Therapeutics Reports First Quarter 2025 Financi... Source: N/A

Financials
	TTM	Q4 2025	FY 2025
Basic EPS	$3.1	$.2	$3.1
Diluted EPS	$2.77	$.15	$2.77
Revenue	$616.29M	$192.57M	$616.29M
Gross Profit	$515.57M	$154.43M	$515.57M
Net Income / Loss	$447.18M	$23.04M	$447.18M
Operating Income / Loss	$123.32M	$50.49M	$123.32M
Cost of Revenue	$100.71M	$38.14M	$100.71M
Net Cash Flow	$-100.7M	$5.08M	$-100.7M
PE Ratio	12.15

Splits
Apr 30, 2012	5:281
Jul 14, 2011	1:50
Sep 25, 2003	1:5